323 related articles for article (PubMed ID: 23514290)
21. [Recommendation for using granulocyte and granulocyte-macrophage growth factor during anti-cancer therapy in children].
Balwierz W; Moryl-Bujakowska A; Balwierz A; Pawińska K
Przegl Lek; 2006; 63(1):1-6. PubMed ID: 16892890
[TBL] [Abstract][Full Text] [Related]
22. Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia.
Crawford J
Semin Oncol; 2003 Aug; 30(4 Suppl 13):24-30. PubMed ID: 14508717
[TBL] [Abstract][Full Text] [Related]
23. Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia.
Cortés de Miguel S; Calleja-Hernández MÁ; Menjón-Beltrán S; Vallejo-Rodríguez I
Support Care Cancer; 2015 Feb; 23(2):547-59. PubMed ID: 25284722
[TBL] [Abstract][Full Text] [Related]
24. Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain--results of the LEARN Study.
Almenar D; Mayans J; Juan O; Bueno JM; Lopez JI; Frau A; Guinot M; Cerezuela P; Buscalla EG; Gasquet JA; Sanchez J
Eur J Cancer Care (Engl); 2009 May; 18(3):280-6. PubMed ID: 19076208
[TBL] [Abstract][Full Text] [Related]
25. A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Münster Study Group.
Welte K; Reiter A; Mempel K; Pfetsch M; Schwab G; Schrappe M; Riehm H
Blood; 1996 Apr; 87(8):3143-50. PubMed ID: 8605328
[TBL] [Abstract][Full Text] [Related]
26. XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy.
Engert A; Griskevicius L; Zyuzgin Y; Lubenau H; del Giglio A
Leuk Lymphoma; 2009 Mar; 50(3):374-9. PubMed ID: 19347726
[TBL] [Abstract][Full Text] [Related]
27. EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer.
Repetto L; Biganzoli L; Koehne CH; Luebbe AS; Soubeyran P; Tjan-Heijnen VC; Aapro MS
Eur J Cancer; 2003 Nov; 39(16):2264-72. PubMed ID: 14556916
[TBL] [Abstract][Full Text] [Related]
28. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
[TBL] [Abstract][Full Text] [Related]
29. Pegylated filgrastim is comparable with filgrastim as support for commonly used chemotherapy regimens: a multicenter, randomized, crossover phase 3 study.
Shi YK; Chen Q; Zhu YZ; He XH; Wang HQ; Jiang ZF; Chang JH; Liu YP; Wang AL; Luo DY; Zhang Y; Ke XY; Li WL; Zhang WJ; Wang XW; Zhang YP; Wang JM; Liu XQ
Anticancer Drugs; 2013 Jul; 24(6):641-7. PubMed ID: 23571496
[TBL] [Abstract][Full Text] [Related]
30. Pegfilgrastim lowers side-effects of chemotherapy.
Sharma DC
Lancet Oncol; 2004 Aug; 5(8):461. PubMed ID: 15309779
[No Abstract] [Full Text] [Related]
31. The safety of full-dose chemotherapy with secondary prophylactic granulocyte colony stimulating factor (G-CSF) following a prior cycle with febrile neutropenia.
Haim N; Shulman K; Goldberg H; Tsalic M
Med Oncol; 2005; 22(3):229-32. PubMed ID: 16110133
[TBL] [Abstract][Full Text] [Related]
32. Abnormal positron emission tomography (PET) scan secondary to the use of hematopoietic growth factors.
Johnston KL; Farnen JP; Manske BR; Go RS
Haematologica; 2005 Dec; 90(12 Suppl):EIM03. PubMed ID: 16464762
[No Abstract] [Full Text] [Related]
33. ESMO recommendations for the application of hematopoietic growth factors.
Greil R; Jost LM;
Ann Oncol; 2005; 16 Suppl 1():i80-2. PubMed ID: 15888768
[No Abstract] [Full Text] [Related]
34. Mecapegfilgrastim in Chemotherapy-Induced Neutropenia: A Profile of Its Use in China.
Al-Salama ZT; Keam SJ
Clin Drug Investig; 2019 Oct; 39(10):1009-1018. PubMed ID: 31489570
[TBL] [Abstract][Full Text] [Related]
35. Colony-stimulating factors for the management of neutropenia in cancer patients.
Dale DC
Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
[TBL] [Abstract][Full Text] [Related]
36. Low-dose filgrastim in patients with breast cancer treated with docetaxel, doxorubicin, and cyclophosphamide.
Ip EJ; Lee-Ma A; Troxell LS; Chan J
Am J Health Syst Pharm; 2008 Aug; 65(16):1552-5. PubMed ID: 18693211
[TBL] [Abstract][Full Text] [Related]
37. Use of filgrastim and pegfilgrastim to support delivery of chemotherapy: twenty years of clinical experience.
Renwick W; Pettengell R; Green M
BioDrugs; 2009; 23(3):175-86. PubMed ID: 19627169
[TBL] [Abstract][Full Text] [Related]
38. Granulocyte colony-stimulating factors used in clinical practice: PoloNord Registry-Based Cohort Italian Study.
Fagnani D; Isa L; Verga MF; Nova P; Casartelli C; Filipazzi V; Danova M; Farina G; Pugliese P; Fava S; Bertolini A; Cimminiello C; Boracchi P; Marano G; Panzarino C;
Tumori; 2014; 100(5):491-8. PubMed ID: 25343541
[TBL] [Abstract][Full Text] [Related]
39. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
[TBL] [Abstract][Full Text] [Related]
40. Colony-stimulating factors for febrile neutropenia.
Carton E; Bellesoeur A; Mir O
N Engl J Med; 2013 Jul; 369(3):285-6. PubMed ID: 23863066
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
